ClinicalTrials.gg
CompletedNCT01422213FOCUSUpdated Aug 5, 2014Results posted

Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder

A Phase 3 interventional study of Placebo and Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-05.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
598
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
16th of 54
598 · median 413
Started
2011
with 4 others
Phase 3
31 of 54
1 open now
Registered
21st of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 16th largest by enrollment, is one of 5 that started in 2011, is one of 31 in phase 3, and was the 21st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Major Depressive Disorder (MDD) is a severe and common psychiatric disorder. Although MDD primarily involves mood disturbances, patients also usually present alterations in cognitive function (attention, memory, executive functioning and psychomotor speed). Even though antidepressants are suggested in the literature to potentially improve cognitive dysfunction in patients with MDD to some degree, there is a lack of adequate and well-controlled studies to investigate this effect. This study will evaluate the efficacy, safety and tolerability of a new antidepressant Vortioxetine versus placebo on cognitive dysfunction in adult patients with MDD.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • MDD
  • Cognitive dysfunction
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is an inpatient in a psychiatric hospital or an outpatient at a psychiatric setting at the time of the study entry.
  • The patient is diagnosed with recurrent MDD according to ™ criteria (classification code 296.3x). The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has received prescribed treatment for a previous episode of depression.
  • The patient has a MADRS total score ≥26.
  • The reported duration of the current MDE is at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • The patient has a score ≥70 on the DSST (number of correct symbols), or ≥42 on the RAVLT (learning) or ≥14 on the RAVLT (memory) at the Baseline Visit.
  • The patient has any current Axis I disorder (™ criteria) other than MDD, confirmed using the MINI.
  • The patient has a current diagnosis or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features.
  • The patient suffers from personality disorders, mental retardation, pervasive development disorder, attention-deficit/hyperactivity disorder, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient has physical, cognitive, or language impairment of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
  • The patient is diagnosed with reading disability (dyslexia).
  • The patient is at significant risk of suicide or has a score ≥5 on Item 10 (suicidal thoughts) of the MADRS, or has attempted suicide \<6 months prior to the Screening Visit.
  • The patient has received electroconvulsive therapy \<6 months prior to the Screening Visit.
  • The current depressive symptoms are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each at the recommended dose.
  • The patient has a history of moderate or severe head trauma (for example, loss of consciousness for more than 1 hour) or other neurological disorders or systemic medical diseases that are, in the opinion of the investigator, likely to affect central nervous system functioning.
  • The patient has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, that has not been in remission for >5 years prior to the first drug dose.
  • The patient has a unstable illness, for example:
  • cardiovascular disease
  • seizure disorder or encephalopathy
  • congestive heart failure
  • cardiac hypertrophy
  • arrhythmia
  • bradycardia (pulse \<50 bpm)
  • respiratory disease
  • hepatic impairment or renal insufficiency
  • metabolic disorder
  • endocrinological disorder
  • gastrointestinal disorder
  • haematological disorder
  • infectious disorder
  • any clinically significant immunological condition
  • dermatological disorder
  • venereal disease
  • The patient has, at the Screening Visit, an abnormal that is, in the investigator's opinion, clinically significant.
  • The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.
  • The patient has previously been exposed to Vortioxetine.

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
598 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Vortioxetine 10 mg

    Drug: Vortioxetine (Lu AA21004)

  • Experimental
    Vortioxetine 20 mg

    Drug: Vortioxetine (Lu AA21004)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores

    DSST assesses psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-s period. Each correct symbol is counted, and the total score ranges from 0 (\< normal functioning) to 133 (\> normal functioning). RAVLT assesses verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded. The scores are standardized by subtracting the overall mean change from baseline from the individual change from baseline and dividing by the standard deviation estimate of the change from baseline. The 2 tests, DSST and RAVLT are each assigned a weight of 0.5, the 2 subtests of RAVLT are each assigned a weight of 0.25.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline to Week 8 in DSST (Number of Correct Symbols)

    Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)." as a description of DSST.

    Time frame: Baseline and Week 8

  2. Change From Baseline to Week 8 in RAVLT (Acquisition)

    Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.

    Time frame: Baseline and Week 8

  3. Change From Baseline to Week 8 in RAVLT (Delayed Recall)

    Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.

    Time frame: Baseline and Week 8

  4. Change From Baseline to Week 8 in the TMT A (Speed of Processing)

    Trail Making Test (TMT) is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part A assesses cognitive processing speed. The lower the score the faster the processing speed.

    Time frame: Baseline and Week 8

  5. Change From Baseline to Week 8 in the TMT B (Executive Function)

    TMT is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part B examines executive functioning and ability to shift cognitive set. The lower the score the faster the ability to shift cognitive set.

    Time frame: Baseline and Week 8

  6. Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function)

    Stroop Colour Naming Test (STROOP) is a cognitive test designed to assess the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises two sheets with 50 words on each, and each word is the name of a colour. On the first sheet, the Congruent STROOP Sheet, the word and ink colour match; on the Incongruent STROOP Sheet, the word and ink colour do not match. For each sheet, the patient has 4 minutes to name the ink colour of each word. When the patient finishes the sheet, or once 4 minutes is up, the clinician notes the time taken and counts the number of correct and incorrect responses. The scale ranges from 0-100, the higher score the greater the cognitive flexibility.

    Time frame: Baseline and Week 8

  7. Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function)

    Time frame: Baseline and Week 8

  8. Change From Baseline to Week 8 in the SRT (Speed of Processing)

    Simple Reaction Time (SRT) is designed to assess psychomotor speed, and Choice Reaction Time (CRT) is designed to assess visual attention. Two computerised tests, part of the CogState battery were used to measure SRT and CRT in milliseconds: * The "detection task" measures SRT: the patient presses a "yes" button, whenever an onscreen playing card is turned over. * The "identification task" measures CRT: the patient presses a "yes" button whenever an onscreen playing card is turned over and is red, or a "no" button if the card is not red.

    Time frame: Baseline and Week 8

  9. Change From Baseline to Week 8 in the CRT (Attention)

    Time frame: Baseline and Week 8

  10. Change From Baseline to Week 8 in MADRS Total Score

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

    Time frame: Baseline and Week 8

  11. Change From Baseline to Week 8 in CGI-S Score

    The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.

    Time frame: Baseline and Week 8

  12. Clinical Status Using CGI-I Score at Week 8

    The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.

    Time frame: Week 8

  13. Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline

    Time frame: Baseline and Week 8

  14. Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10)

    Time frame: Week 8

  15. Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score

    Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables. In the week 1 analysis the vortioxetine 10 and 20 mg groups were pooled because patients randomized to vortioxetine 20 mg received vortioxetine 10 mg in the first week of the study.

    Time frame: Baseline and Week 1

  16. Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score

    Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables.

    Time frame: Baseline and Week 8

  17. Risk of Suicidality Using C-SSRS Scores

    The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with subquestions that assess severity. The tool was administered via an interview with the patient. For 2 patients in each treament group (6 in total) the CSSRS assessments are missing during study.

    Time frame: Up to 8 weeks

07

Results

Posted Aug 5, 2014

Participant flow

Patients were selected from psychiatric settings, outpatient clinics, and inpatient hospitals; and recruited via ads (if allowed in the country) or referrals (from general practitioners). A Pre-Randomisation Form completed by the site for each patient was reviewed by the CRO Medical Expert to confirm patient eligibility prior to randomisation.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 10 mgVortioxetine 20 mg
Started196195207
Completed163173178
Not completed332229
Withdrew: Adverse event8711
Withdrew: Lack of efficacy1022
Withdrew: Non-compliance with study drug010
Withdrew: Protocol violation024
Withdrew: Withdrawal of consent735
Withdrew: Lost to follow-up335
Withdrew: Administrative or other reason(s)542

Outcome measures

PrimaryChange From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores

DSST assesses psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-s period. Each correct symbol is counted, and the total score ranges from 0 (\< normal functioning) to 133 (\> normal functioning). RAVLT assesses verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded. The scores are standardized by subtracting the overall mean change from baseline from the individual change from baseline and dividing by the standard deviation estimate of the change from baseline. The 2 tests, DSST and RAVLT are each assigned a weight of 0.5, the 2 subtests of RAVLT are each assigned a weight of 0.25.

Time frame:
Baseline and Week 8
Reported as:
Mean · z score
Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores
z scorePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores-0.235 ± 0.0530.128 ± 0.0520.095 ± 0.051
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = <0.0001 (To adjust for multiplicity, the 10 and 20 mg doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.05/2 = 0.025.) · Mean difference (final values): 0.363 · 95% CI 0.22 to 0.50
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = <0.0001 (To adjust for multiplicity, the 10 and 20 mg doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.05/2 = 0.025.) · Mean difference (final values): 0.330 · 95% CI 0.19 to 0.47
SecondaryChange From Baseline to Week 8 in DSST (Number of Correct Symbols)

Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)." as a description of DSST.

Time frame:
Baseline and Week 8
Reported as:
Mean · number of correct symbols
Change From Baseline to Week 8 in DSST (Number of Correct Symbols)
number of correct symbolsPlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in DSST (Number of Correct Symbols)4.83 ± 0.639.03 ± 0.639.09 ± 0.61
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = <0.0001 (To adjust for multiplicity, the 10 and 20 mg doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.05/2 = 0.025.) · Mean difference (final values): 4.20 · 95% CI 2.50 to 5.90
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = <0.0001 (To adjust for multiplicity, the 10 and 20 mg doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.05/2 = 0.025.) · Mean difference (final values): 4.26 · 95% CI 2.57 to 5.94
SecondaryChange From Baseline to Week 8 in RAVLT (Acquisition)

Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.

Time frame:
Baseline and Week 8
Reported as:
Mean · number of words correctly recalled
Change From Baseline to Week 8 in RAVLT (Acquisition)
number of words correctly recalledPlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in RAVLT (Acquisition)3.06 ± 0.344.08 ± 0.343.65 ± 0.33
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = 0.0287 (To adjust for multiplicity, the 10 and 20 mg doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.05/2 = 0.025.) · Mean difference (final values): 1.02 · 95% CI 0.11 to 1.93
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = 0.1988 (To adjust for multiplicity, the 10 and 20 mg doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.05/2 = 0.025.) · Mean difference (final values): 0.59 · 95% CI -0.31 to 1.50
SecondaryChange From Baseline to Week 8 in RAVLT (Delayed Recall)

Rey Auditory Verbal Learning Task (RAVLT) is a cognitive test designed to assess verbal learning and memory, including immediate memory, efficiency of learning, retroactive and proactive interference effects, and encoding versus retrieval. It consists of a number of tasks, including immediate recall and delayed recall. The number of words correctly recalled on each task is recorded.

Time frame:
Baseline and Week 8
Reported as:
Mean · number of words correctly recalled
Change From Baseline to Week 8 in RAVLT (Delayed Recall)
number of words correctly recalledPlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in RAVLT (Delayed Recall)0.91 ± 0.181.63 ± 0.181.56 ± 0.17
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = 0.0033 (Since the p-value for RAVLT acquisition for 10 mg was \>0.025, the p-value for this test is nominal.) · Mean difference (final values): 0.71 · 95% CI 0.24 to 1.19
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = 0.0073 (Since the p-value for RAVLT acquisition for 20 mg was \>0.025, the p-value for this test is nominal.) · Mean difference (final values): 0.65 · 95% CI 0.17 to 1.12
SecondaryChange From Baseline to Week 8 in the TMT A (Speed of Processing)

Trail Making Test (TMT) is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part A assesses cognitive processing speed. The lower the score the faster the processing speed.

Time frame:
Baseline and Week 8
Reported as:
Mean · seconds
Change From Baseline to Week 8 in the TMT A (Speed of Processing)
secondsPlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in the TMT A (Speed of Processing)-7.07 ± 1.00-10.84 ± 1.00-10.87 ± 0.97
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = 0.0061 (No adjustment for multiplicity was made.) · Mean difference (final values): -3.76 · 95% CI -6.45 to -1.08
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = 0.0052 (No adjustment for multiplicity was made.) · Mean difference (final values): -3.80 · 95% CI -6.46 to -1.14
SecondaryChange From Baseline to Week 8 in the TMT B (Executive Function)

TMT is a cognitive test designed to assess scanning, visuomotor tracking, executive function, and cognitive flexibility. It consists of two parts, A and B: the patient must draw lines to connect consecutively numbered circles (part A) and then connect consecutively numbered and lettered circles alternating between the two sequences (part B). The time taken to complete the two parts is recorded. Part B examines executive functioning and ability to shift cognitive set. The lower the score the faster the ability to shift cognitive set.

Time frame:
Baseline and Week 8
Reported as:
Mean · seconds
Change From Baseline to Week 8 in the TMT B (Executive Function)
secondsPlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in the TMT B (Executive Function)-13.84 ± 2.00-21.41 ± 2.00-22.85 ± 1.95
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = 0.0058 (No adjustment for multiplicity was made.) · Mean difference (final values): -7.57 · 95% CI -12.93 to -2.20
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = 0.0009 (No adjustment for multiplicity was made.) · Mean difference (final values): -9.01 · 95% CI -14.32 to -3.70
SecondaryChange From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function)

Stroop Colour Naming Test (STROOP) is a cognitive test designed to assess the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises two sheets with 50 words on each, and each word is the name of a colour. On the first sheet, the Congruent STROOP Sheet, the word and ink colour match; on the Incongruent STROOP Sheet, the word and ink colour do not match. For each sheet, the patient has 4 minutes to name the ink colour of each word. When the patient finishes the sheet, or once 4 minutes is up, the clinician notes the time taken and counts the number of correct and incorrect responses. The scale ranges from 0-100, the higher score the greater the cognitive flexibility.

Time frame:
Baseline and Week 8
Reported as:
Mean · seconds
Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function)
secondsPlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in Congruent STROOP Time to Complete (Executive Function)-5.97 ± 0.93-9.97 ± 0.93-10.43 ± 0.90
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = 0.0018 (No adjustment for multiplicity was made.) · Mean difference (final values): -4.00 · 95% CI -6.50 to -1.49
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = 0.0005 (No adjustment for multiplicity was made.) · Mean difference (final values): -4.45 · 95% CI -6.93 to -1.97
SecondaryChange From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function)
Time frame:
Baseline and Week 8
Reported as:
Mean · seconds
Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function)
secondsPlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in Incongruent STROOP Time to Complete (Executive Function)-10.94 ± 1.48-17.69 ± 1.48-17.45 ± 1.44
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = 0.0010 (No adjustment for multiplicity was made.) · Mean difference (final values): -6.75 · 95% CI -10.76 to -2.74
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = 0.0013 (No adjustment for multiplicity was made.) · Mean difference (final values): -6.52 · 95% CI -10.49 to -2.54
SecondaryChange From Baseline to Week 8 in the SRT (Speed of Processing)

Simple Reaction Time (SRT) is designed to assess psychomotor speed, and Choice Reaction Time (CRT) is designed to assess visual attention. Two computerised tests, part of the CogState battery were used to measure SRT and CRT in milliseconds: * The "detection task" measures SRT: the patient presses a "yes" button, whenever an onscreen playing card is turned over. * The "identification task" measures CRT: the patient presses a "yes" button whenever an onscreen playing card is turned over and is red, or a "no" button if the card is not red.

Time frame:
Baseline and Week 8
Reported as:
Mean · log10 (ms)
Change From Baseline to Week 8 in the SRT (Speed of Processing)
log10 (ms)PlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in the SRT (Speed of Processing)-0.007 ± 0.009-0.053 ± 0.009-0.037 ± 0.009
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = 0.0002 (No adjustment for multiplicity was made.) · Mean difference (final values): -0.046 · 95% CI -0.07 to -0.02
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = 0.0157 (No adjustment for multiplicity was made.) · Mean difference (final values): -0.029 · 95% CI -0.05 to -0.01
SecondaryChange From Baseline to Week 8 in the CRT (Attention)
Time frame:
Baseline and Week 8
Reported as:
Mean · log10 (ms)
Change From Baseline to Week 8 in the CRT (Attention)
log10 (ms)PlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in the CRT (Attention)-0.015 ± 0.007-0.046 ± 0.007-0.023 ± 0.006
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = 0.0005 (No adjustment for multiplicity was made.) · Mean difference (final values): -0.032 · 95% CI -0.05 to -0.01
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = 0.3549 (No adjustment for multiplicity was made.) · Mean difference (final values): -0.008 · 95% CI -0.03 to 0.01
SecondaryChange From Baseline to Week 8 in MADRS Total Score

The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline to Week 8 in MADRS Total Score
units on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in MADRS Total Score-10.85 ± 0.64-15.56 ± 0.63-17.55 ± 0.62
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = <0.0001 (No adjustment for multiplicity was made.) · Mean difference (final values): -4.70 · 95% CI -6.45 to -2.96
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = <0.0001 (No adjustment for multiplicity was made.) · Mean difference (final values): -6.70 · 95% CI -8.43 to -4.98
SecondaryChange From Baseline to Week 8 in CGI-S Score

The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change From Baseline to Week 8 in CGI-S Score
units on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 in CGI-S Score-1.15 ± 0.08-1.80 ± 0.08-2.00 ± 0.08
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = <0.0001 (No adjustment for multiplicity was made.) · Mean difference (final values): -0.65 · 95% CI -0.88 to -0.42
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = <0.0001 (No adjustment for multiplicity was made.) · Mean difference (final values): -0.85 · 95% CI -1.08 to -0.62
SecondaryClinical Status Using CGI-I Score at Week 8

The Clinical Global Impression - Global Improvement (CGI-I) is a 7-point scale rated from 1 (very much improved) to 7 (very much worse). The investigator rated the patient's overall improvement relative to baseline, whether or not, in the opinion of the investigator, this was entirely due to the drug treatment.

Time frame:
Week 8
Reported as:
Mean · units on a scale
Clinical Status Using CGI-I Score at Week 8
units on a scalePlaceboVortioxetine 10 mgVortioxetine 20 mg
Clinical Status Using CGI-I Score at Week 82.85 ± 0.082.24 ± 0.081.99 ± 0.07
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Mixed Models Analysis · p = <0.0001 (No adjustment for multiplicity was made.) · Mean difference (final values): -0.61 · 95% CI -0.81 to -0.40
  • Placebo vs Vortioxetine 20 mg · Mixed Models Analysis · p = <0.0001 (No adjustment for multiplicity was made.) · Mean difference (final values): -0.86 · 95% CI -1.06 to -0.65
SecondaryProportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline
Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline
percentage of participantsPlaceboVortioxetine 10 mgVortioxetine 20 mg
Proportion of Responders at Week 8 (Response Defined as a >=50% Decrease in the MADRS Total Score From Baseline29.447.758.8
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.0002 (Wald's Test. No adjustment for multiplicity was made.) · Odds ratio (or): 2.19 · 95% CI 1.44 to 3.33
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = <0.0001 (Wald's Test. No adjustment for multiplicity was made.) · Odds ratio (or): 3.43 · 95% CI 2.26 to 5.21
SecondaryProportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10)
Time frame:
Week 8
Reported as:
Number · percentage of participants
Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10)
percentage of participantsPlaceboVortioxetine 10 mgVortioxetine 20 mg
Proportion of Remitters at Week 8 (Remission is Defined as a MADRS Total Score <=10)17.029.538.2
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · Regression, Logistic · p = 0.0030 (Wald's Test. No adjustment for multiplicity was made.) · Odds ratio (or): 2.09 · 95% CI 1.29 to 3.41
  • Placebo vs Vortioxetine 20 mg · Regression, Logistic · p = <0.0001 (Wald's Test. No adjustment for multiplicity was made.) · Odds ratio (or): 3.13 · 95% CI 1.95 to 5.03
SecondaryChange From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score

Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables. In the week 1 analysis the vortioxetine 10 and 20 mg groups were pooled because patients randomized to vortioxetine 20 mg received vortioxetine 10 mg in the first week of the study.

Time frame:
Baseline and Week 1
Reported as:
Least squares mean · z score
Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score
z scorePlaceboVortioxetine 10 mg
Change From Baseline to Week 1 Using the MADRS Total Score and the Composite Z-score-0.079 ± 0.0500.042 ± 0.037
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.0393 (No adjustment for multiplicity was made.) · Mean difference (final values): 0.12 · 95% CI 0.01 to 0.24
SecondaryChange From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score

Effect on cognitive dysfunction after correcting for the effect on depressive symptoms. The estimation of the effect on cognitive dysfunction after correcting for the effect on depressive symptoms was based on the composite z-score and the MADRS total score. The effect was estimated in an ANCOVA model using the composite z-score at week 1 as dependent variable and the change from baseline to week 1 in the MADRS total score, the baseline MADRS total score, the baseline composite z-score, the treatment group and site as independent variables.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · z score
Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score
z scorePlaceboVortioxetine 10 mgVortioxetine 20 mg
Change From Baseline to Week 8 Using the MADRS Total Score and the Composite Z-score-0.189 ± 0.0500.041 ± 0.049-0.036 ± 0.048
Statistical analysis
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.0007 (No adjustment for multiplicity was made.) · Mean difference (final values): 0.23 · 95% CI 0.10 to 0.36
  • Placebo vs Vortioxetine 20 mg · ANCOVA · p = 0.0246 (No adjustment for multiplicity was made.) · Mean difference (final values): 0.15 · 95% CI 0.02 to 0.29
SecondaryRisk of Suicidality Using C-SSRS Scores

The Columbia-Suicide Severity Rating Scale (C-SSRS) was developed by researchers at Columbia University as a tool to systematically assess suicidal ideation and behaviour in patients during participation in a clinical study. The C-SSRS is composed of questions that address suicidal behaviour and questions that address suicidal ideation, with subquestions that assess severity. The tool was administered via an interview with the patient. For 2 patients in each treament group (6 in total) the CSSRS assessments are missing during study.

Time frame:
Up to 8 weeks
Reported as:
Number · participants
Risk of Suicidality Using C-SSRS Scores
participantsPlaceboVortioxetine 10 mgVortioxetine 20 mg
No suicidal ideation or behaviour173175178
Any non-suicidal self-injurious behavior000
Any suicidal ideation or behaviour211827

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/196 (1%)31/196 (15.8%)
Vortioxetine 10 mg—0/195 (0%)48/195 (24.6%)
Vortioxetine 20 mg—2/207 (1%)66/207 (31.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 10 mgVortioxetine 20 mg
Hiatus herniaGastrointestinal disorders1/1960/1950/207
CholecystitisHepatobiliary disorders1/1960/1950/207
Type 1 diabetes mellitusMetabolism and nutrition disorders0/1960/1951/207
HypertensionVascular disorders0/1960/1951/207
Most frequent other events
Most frequent other events
EventPlaceboVortioxetine 10 mgVortioxetine 20 mg
NauseaGastrointestinal disorders8/19632/19543/207
HeadacheNervous system disorders14/19616/19526/207
NasopharyngitisInfections and infestations10/1967/1959/207

Baseline characteristics

Age + Gender: all-patients-treated set (APTS) - all patients in the APRS who took at least one dose of IMP. Study-specific Measures: full-analysis set (FAS) - all patients in the APTS who had a valid baseline assessment and at least one valid post-baseline assessment of the DSST, RAVLT (learning \[acquisition\]), and RAVLT (memory \[delayed recall\]).

Age, Continuous
Age, Continuous(years)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean45.6 ± 12.145.4 ± 12.246.1 ± 11.845.7 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Female129134133396
Male676174202
DSST: Baseline Total Score
DSST: Baseline Total Score(units on a scale)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean42.38 ± 13.7641.96 ± 12.5641.61 ± 12.7241.98 ± 13.00
RAVLT: Baseline Total Score
RAVLT: Baseline Total Score(correct words)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean22.14 ± 5.7022.34 ± 5.7622.64 ± 5.8822.38 ± 5.77
TMT A: Baseline Total Score
TMT A: Baseline Total Score(seconds)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean48.71 ± 24.7346.51 ± 24.1246.23 ± 26.6647.13 ± 25.20
TMT B: Baseline Total Score
TMT B: Baseline Total Score(seconds)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean105.05 ± 52.99101.82 ± 51.68102.94 ± 52.43103.27 ± 52.30
STROOP Congruent: Baseline Total Score
STROOP Congruent: Baseline Total Score(seconds)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean49.97 ± 24.8649.59 ± 24.6550.01 ± 27.5849.86 ± 25.72
STROOP Incongruent: Baseline Total Score
STROOP Incongruent: Baseline Total Score(seconds)PlaceboVortioxetine 10 mgVortioxetine 20 mgTotal
Mean85.66 ± 39.1585.03 ± 41.0983.62 ± 41.4084.75 ± 40.51

4 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Nohr AK, Lindow M, Forsingdal A, Demharter S, Nielsen T, Buller R, Moltke I, Vitezic M, Albrechtsen A. A large-scale genome-wide gene expression analysis in peripheral blood identifies very few differentially expressed genes related to antidepressant treatment and response in patients with major depressive disorder. Neuropsychopharmacology. 2021 Jun;46(7):1324-1332. doi: 10.1038/s41386-021-01002-9. Epub 2021 Apr 8. PubMed 33833401 ↗
  • McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. J Clin Psychiatry. 2017 Jan;78(1):115-121. doi: 10.4088/JCP.16m10744. PubMed 27780334 ↗
  • McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014 Oct;17(10):1557-67. doi: 10.1017/S1461145714000546. Epub 2014 Apr 30. PubMed 24787143 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011 and a primary completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2011
First posted
Aug 23, 2011
Start
Dec 2011
Primary completionActual
May 2013
Results first posted
Aug 5, 2014
Last update
Aug 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01422213
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 23, 2011
Start date
Dec 2011
Primary completion
May 2013
Results posted
Aug 5, 2014
Last update
Aug 5, 2014

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion